COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of of APL-2 Therapy in Patients Geographic Atrophy (FILLY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02503332
Recruitment Status : Completed
First Posted : July 20, 2015
Last Update Posted : November 19, 2019
Information provided by (Responsible Party):
Apellis Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 11, 2018
Actual Study Completion Date : January 11, 2018
Certification/Extension First Submitted : November 13, 2019
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 4, 2020